'''Crystal Structure of the multi-drug resistant mutant subtype B HIV protease complexed with TL-3 inhibitor'''
===Crystal Structure of the multi-drug resistant mutant subtype B HIV protease complexed with TL-3 inhibitor===
==Overview==
<!--
Although a majority of HIV-1 infections in Brazil are caused by the subtype B virus (also prevalent in the United States and Western Europe), viral subtypes F and C are also found very frequently. Genomic differences between the subtypes give rise to sequence variations in the encoded proteins, including the HIV-1 protease. The current anti-HIV drugs have been developed primarily against subtype B and the effects arising from the combination of drug-resistance mutations with the naturally existing polymorphisms in non-B HIV-1 subtypes are only beginning to be elucidated. To gain more insights into the structure and function of different variants of HIV proteases, we have determined a 2.1 A structure of the native subtype F HIV-1 protease (PR) in complex with the protease inhibitor TL-3. We have also solved crystal structures of two multi-drug resistant mutant HIV PRs in complex with TL-3, from subtype B (Bmut) carrying the primary mutations V82A and L90M, and from subtype F (Fmut) carrying the primary mutation V82A plus the secondary mutation M36I, at 1.75 A and 2.8 A resolution, respectively. The proteases Bmut, Fwt and Fmut exhibit sevenfold, threefold, and 54-fold resistance to TL-3, respectively. In addition, the structure of subtype B wild type HIV-PR in complex with TL-3 has been redetermined in space group P6(1), consistent with the other three structures. Our results show that the primary mutation V82A causes the known effect of collapsing the S1/S1' pockets that ultimately lead to the reduced inhibitory effect of TL-3. Our results further indicate that two naturally occurring polymorphic substitutions in subtype F and other non-B HIV proteases, M36I and L89M, may lead to early development of drug resistance in patients infected with non-B HIV subtypes.
The line below this paragraph, {{ABSTRACT_PUBMED_17467738}}, adds the Publication Abstract to the page
(as it appears on PubMed at http://www.pubmed.gov), where 17467738 is the PubMed ID number.
-->
{{ABSTRACT_PUBMED_17467738}}
==About this Structure==
==About this Structure==
Line 30:
Line 34:
[[Category: Protease-inhibitor complex]]
[[Category: Protease-inhibitor complex]]
[[Category: Tl-3 inhibitor]]
[[Category: Tl-3 inhibitor]]
''Page seeded by [http://oca.weizmann.ac.il/oca OCA ] on Sun May 4 12:15:10 2008''
''Page seeded by [http://oca.weizmann.ac.il/oca OCA ] on Tue Jul 29 01:06:34 2008''
Revision as of 01:06, 29 July 2008
This article has been automatically seeded. Changes to this page should pertain to the PDB entry only and not to the protein or biomolecule in general.
Crystal Structure of the multi-drug resistant mutant subtype B HIV protease complexed with TL-3 inhibitorCrystal Structure of the multi-drug resistant mutant subtype B HIV protease complexed with TL-3 inhibitor
Full crystallographic information is available from OCA.
ReferenceReference
Structural characterization of B and non-B subtypes of HIV-protease: insights into the natural susceptibility to drug resistance development., Sanches M, Krauchenco S, Martins NH, Gustchina A, Wlodawer A, Polikarpov I, J Mol Biol. 2007 Jun 15;369(4):1029-40. Epub 2007 Mar 24. PMID:17467738
